TY - JOUR
T1 - Adjuvant treatment for Stage i seminoma
T2 - Why radiotherapy is better than carboplatin
AU - Yathiraj, Prahlad
AU - Sharan, Krishna
AU - Fernandes, Donald
AU - Vidyasagar, M.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Adjuvant treatment options for Stage I seminoma include active surveillance, chemotherapy, and radiotherapy. Active surveillance may not be ideal for the average Indian patient. Of the two accepted adjuvant therapy options, namely single-dose carboplatin chemotherapy and radiotherapy to the retroperitoneal nodes, though it intuitively appears more appealing, a deeper review reveals the potential drawbacks of chemotherapy. This article highlights the misconceptions regarding carboplatin and provides reasons for an argument why radiotherapy is better when a patient with Stage I seminoma chooses to undergo adjuvant treatment.
AB - Adjuvant treatment options for Stage I seminoma include active surveillance, chemotherapy, and radiotherapy. Active surveillance may not be ideal for the average Indian patient. Of the two accepted adjuvant therapy options, namely single-dose carboplatin chemotherapy and radiotherapy to the retroperitoneal nodes, though it intuitively appears more appealing, a deeper review reveals the potential drawbacks of chemotherapy. This article highlights the misconceptions regarding carboplatin and provides reasons for an argument why radiotherapy is better when a patient with Stage I seminoma chooses to undergo adjuvant treatment.
UR - http://www.scopus.com/inward/record.url?scp=85012134744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012134744&partnerID=8YFLogxK
U2 - 10.4103/0973-1482.176171
DO - 10.4103/0973-1482.176171
M3 - Review article
C2 - 28169230
AN - SCOPUS:85012134744
SN - 0973-1482
VL - 12
SP - 1216
EP - 1219
JO - Journal of Cancer Research and Therapeutics
JF - Journal of Cancer Research and Therapeutics
IS - 4
ER -